ox-i-KOE-done 
11 yr should be tolerating a minimum opioid dose of 20 mg of oxycodone or equivalent for 5 days before initiating extended-release oxycodone therapy).Absorption: Well absorbed from the GI tract.
Distribution: Widely distributed. Crosses the placenta; enters breast milk.
Protein Binding: 38–45%.
Metabolism/Excretion: Mostly metabolized by the liver by the CYP3A4 isoenzyme; also metabolized by the CYP2D6 to a minor extent.
Half-life: 2–3 hr.
Contraindicated in:
Use Cautiously in:
CV: orthostatic hypotension.
Derm: flushing, sweating.
EENT: blurred vision, diplopia, miosis.
Endo: adrenal insufficiency.
GI: constipation, dry mouth, choking, GI obstruction, nausea, vomiting.
GU: urinary retention.
Neuro: confusion, sedation, dizziness, dysphoria, euphoria, floating feeling, hallucinations, headache, unusual dreams.
Resp: RESPIRATORY DEPRESSION (INCLUDING CENTRAL SLEEP APNEA AND SLEEP-RELATED HYPOXEMIA).
Misc: physical dependence, psychological dependence, tolerance.
Drug-Drug:
50 kg): Opioid-naive patients — 5–10 mg every 3–4 hr initially, as needed. Once optimal analgesia is obtained, patients with chronic pain may be converted to an equivalent 24-hr dose given in 2 divided doses as extended-release tablets every 12 hr.11 yr): 0.05–0.15 mg/kg every 4–6 hr as needed, as immediate-release product. Once optimal analgesia is obtained, patients with chronic pain may be converted to an equivalent 24-hr dose given in 2 divided doses as extended-release tablets every 12 hr.Hepatic Impairment
Therapeutic Classification: opioid analgesics
Pharmacologic Classification: opioid agonists, opioid agonists nonopioid analgesic combinations
(Generic available)
NDC Code*